Spending For Science

I am puzzled at some of John Gibbons's remarks in the article about the Office of Technology Assessment (The Scientist, Jan. 20, 1992, page 11). He seems to think we have large deficits because of the tax cuts of the early 1980s. In fact, the annual federal budget has roughly doubled in the past decade, while inflation has been about 50 percent, and the average salary has increased by about 50 percent. In the last three years alone, the federal budget has increased from a trillion dollars or

Written byKarl Stengel
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

In the last three years alone, the federal budget has increased from a trillion dollars or so to the current level of more than $1.4 trillion. Had the federal budget been frozen as recently as 1989, the budget would have been balanced by this year, leaving a $50 billion to $100 billion annual surplus. Spending, not tax cuts, is the source of the deficits.

As far as his remark that the federal government cannot increase science funding because he doesn't know where the money will come from, if even 10 percent of the $400 billion increase of the last three years had been devoted to science, federally funded science would be rolling in money. In fact, that $400 billion (none of which went to the military, by the way) is more than the military budget (about $300 billion), nearly the amount of the savings and loan losses (about $500 billion), ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies